<DOC>
	<DOC>NCT02490150</DOC>
	<brief_summary>To evaluate if the administration of corifollitropin alfa on day 7 instead of on day 5 after pre-treatment with oral contraceptive pill results in a reduced total rFSH (recombinant follicle stimulating hormone ) consumption in a GnRH antagonist protocol in donors.</brief_summary>
	<brief_title>Corifollitropin Alfa on D5 Versus D7 After Contraceptive Pill</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives, Oral, Combined</mesh_term>
	<criteria>Women 1835 y old ,with regular spontaneous menstrual cycles of 2530 days length Who had vaginal sexual intercourse or have no inconvenient for vaginal explorations Donors can´t have more than 6 children (neither own or after donations) Not be adopted or being born after a gamete donation pregnancy BMI between 1828 kg/m2 Height &gt; 1.55cm Gynecological and general examination with Pap smear, HIV, HCV (hepatitis C virus ), HBV (hepatitis B virus ) and RPR(rapid plasma reagin test ) negative serology, and with normal karyotype No abnormal Psychological profile Discard any disease: blood disorders, neurodegenerative/psychiatric diseases, Fragile X Syndrome, cystic fibrosis carrier, oncology diseases. Without psychological/psychiatric family history Will conform to the protocol for the duration of the study Willingness of adhesion to protocol during the whole study period Signed informed consent Polycystic ovarian syndrome Antral follicle count &gt; 20 Hypersensitivity to the active substance or any of the excipients Abnormal vaginal bleeding of unknown ethiology Presence of ovarian cysts or increased size ovaries History of ovarian hyperstimulation syndrome Previous controlled ovarian stimulation cycle with more than 30 follicles ≥ 11mm Previous abdominal surgery that contraindicated the practice of follicular puncture HIV, HCV, HBV positive serology in women or partner Important systemic diseases that could interfere with gonadotrophin treatment (ovarian and hypothalamic tumors…)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Corifollitropin alfa</keyword>
	<keyword>Stimulation protocol</keyword>
</DOC>